EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Datwyler Pharma Packaging
Senior Manager Global Scientific Affairs
Renaud Janssen PhD is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging He frequently presents on international conferences on subjects related to elastomeric and aluminiumplastic closures for pharmaceutical applications Renaud also serves on several standardisation and pharmacopoeia committees as well as on industry task forces
Articles
Navigating Regulatory Frameworks: “Generic Approvals in Latin America’s Two Giants- Brazil & Mexico
The pharmaceutical products that can often be substituted with a previously approved brandnew product manufactured without the innovators license and marketed upon the expiry of the patent are called as generics Generics account for the of the global pharmaceutical prescription sales The Generic Drugs segment is expanding at a faster rate and is expected to achieve Compound Annual Growth Rate CA...
Research Insights
Validation Of A Liquid Chromatographic Method For The Pharmaceutical Quality Control Of Products Containing Elacridar
Abstract Many anticancer drugs have an impaired bioavailability and poor brain penetration because they are substrates to drug efflux pumps such as Pglycoprotein and Breast Cancer Resistance Protein Elacridar is a strong inhibitor of these two drug efflux pumps and therefore has great potential to improve oral absorption and brain penetration of many anticanc
Case Studies
Applying Data Mining Techniques To Medical Time Series: An Empirical Case Study
Abstract One of the major challenges in the medical domain today is how to exploit the huge amount of data that this field generates To do this approaches are required that are capable of discovering knowledge that is useful for decision making in the medical field Time series are data types that are common in the medical domain and require specialized analy
Techno Trends
Aptar Pharma and Medtech firms to Develop Novel Auto-injector
Aptar Pharma a segment of AptarGroup entered into an exclusive development and license agreement with BD Becton Dickinson and Company a medtech firm to jointly develop a novel autoinjector In developing this injector Aptar Pharma uses its twostep autoinjector technology and prefillable syringes from BD Autoinjectors are designed
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Covid -19 and Nanoparticles
Ramendra Pati Pandey is an Assistant Professor in the Department of Biotechnology/Microbiology/Biomedical Engineering at the SRM University, Delhi-NCR, Sonepat. He was a FAPESP Post-Doctoral Fellow a very prestigious fellowship of Latin America at the Department of Medicine-InCor/HC-FMUSP, University of Sao Paulo, Brazil.
Deepika has completed here master degree from Department of Biotechnology, Deenbandhu Choturam University and Technology, Sonepat, Haryana, India.
Reshma completed her master's degree from the Royal Global University in Guwahati, Assam, India's department of Biotechnology.
Neehasri holds a master's degree in Zoology from Gauhati University in Guwahati, Assam, India, and has also passed the B.Ed. professional exam.
Harnessing Artificial Intelligence
Anita-Ioana Visan, a Scientific Researcher 2nd degree, at the Laser-Surface-Plasma Interactions (LSPI) Laboratory, Lasers Department, National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, is an expert in nanopowders synthesis and characterisation, as well as thin coatings of calcium phosphates, biopolymers, flavonoids, antibiotics, and antimicrobial peptides synthesized by Pulsed Laser Deposition, Matrix Assisted Pulsed Laser Evaporation, and Combinatorial-MAPLE. Moreover, she has a profound knowledge of thin films characterisation methods, including UV-Vis, FTIR, XRD, SEM, AFM, fluorescence microscopy, electrochemical, magnetic induction, biodegradation, and antimicrobial tests. With her current research focusing on the cutting-edge fields of artificial neural networks, drug repurposing, and pharmaceutical AI, she is paving the way for innovative solutions that have the potential to revolutionise the field of medicine. If you would like to contact her, please use the following email address: anita.visan@inflpr.ro. Furthermore, you can find her professional profile at https://orcid.org/0000-0003-0539-4160.
Irina Negut is a Scientific Researcher 2nd degree, at the National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, Romania. She has important experience in fabricating and investigating the characteristics and (bio) functionality of nano-sized/-structured materials (including composite and hybrid particles, thin films and laser-processed coatings). Her research activity includes coating synthesis by laser-assisted techniques. She is also highly experienced in evaluating the compositional and microstructural aspects of nanomaterials and coatings, but also in assessing their optical, thermal, electrical, and electrochemical properties. If you would like to contact her, please use the following email address: negut.irina@inflpr.ro. Her professional profile can be found at https://orcid.org/0000-0003-4038-7548.
Novel Claudin Targeted C-terminal Clostridium Perfringens Enterotoxin Conjugated Anticancer Nanotherapeutics
Sushil Y. Raut Assistant Professor and Head of Research Promotion Cell, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune. He has over 12 years of teaching and research experience. He has more than 25 research and review publications. He filed 3 Indian patents and over 20 national as well as international presentations in his credits. He is recipient of international research mobility fellowship and other prestigious awards.
Tanaji D. Nandgude, Associate Professor, Dr. D. Y. Patil institute of Pharmaceutical Sciences and Research, Pimpri, Pune. He has 15 years of experience in teaching and research in pharmacy. He has more than 50 research/review papers, more than 60 research paper presentations, 5 book publications and granted projects to his credit. He is recipient of “Young Researcher Award”.
Approach for Producing Pharmaceuticals in Layer By Layer Fashion: Additive Manufacturing
Lakshmi usha Ayalasomayajula is an Assistant Professor in the Department of Pharmaceutical Technology at M.R. College of Pharmacy, India with 9 years of teaching and research experience. She has published 30 papers in international and national journals and has presented 20 papers in various conferences as author and co-author.
Earle Radha Rani is working as assistant professor in department of pharmaceutical technology, Maharajah’s College of Pharmacy, Andhra Pradesh, India. She has 7 years of teaching experience and has published over 30 research and review articles in several reputed national and international journals. Her areas of interest include novel drug delivery systems.
AVS Ksheera Bhavani is working as assistant professor in department of Pharmaceutical Biotechnology, Maharajah’s College of Pharmacy, Andhra Pradesh, India. She has about 10 years of teaching experience and has published over 10 research and review articles in several reputed national and international journals. Her areas of interest include novel drug delivery systems.
kishore pathivada ,an under graduate from Maharajah's college of pharmacy, Vizianagaram, during the year, 2017-21. I Qualified GPAT-2021 with AIR 705 and I also got qualified in NIPER JEE-2021 with AIR 62.Currently Iam pursuing my master's degree in Dept. of pharmaceutical Analysis at NIPER Mohali, Punjab which is one of the top most reputed colleges in INDIA in the field of Pharmaceutical Sciences and Research.
press releasesRead more...
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
Ferring Pharmaceuticals and Gameto sign agreement for proposed acquisition
Ferring Pharmaceuticals and Gameto today announced that they have signed an agreement for a global transaction under which Ferring would acquire Gameto Completion remains subject to customary and other closing conditions Until closing the companies will continue to operate independently
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of cancer metabolic autoimmune and other major diseases today announced that a New Indication Application for sintilimab in combination with Nolgileuce...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
The Menarini Group Menarini a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biot...
Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug
Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...
EventsRead more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
AstraZeneca and Oracle Launch Global AI Collaboration to Optimise Clinical Trials
AstraZeneca and Oracle Health and Life Sciences have launched a global collaboration to use artificial intelligence AI realworld data and cloud technology to improve clinical trial efficiency and patient outcomes The collaboration will combine AstraZenecas expertise in drug development clinical rese...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies